European Medicines Agency Committee to Extend the Use of Veklury (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis
Portfolio Pulse from Benzinga Newsdesk
The European Medicines Agency's CHMP granted a positive opinion for the use of Gilead Sciences' Veklury (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis. The European Commission will review the recommendation.
May 26, 2023 | 7:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Gilead Sciences' Veklury (remdesivir) received a positive opinion from EMA's CHMP for use in COVID-19 patients with severe renal impairment, potentially expanding its market.
The positive opinion from EMA's CHMP for the use of Veklury in COVID-19 patients with severe renal impairment, including those on dialysis, could lead to an expanded market for the drug. If the European Commission adopts the recommendation, Veklury will become the first and only authorized antiviral COVID-19 treatment that can be used across all stages of renal disease. This could potentially increase demand for the drug and have a positive impact on Gilead Sciences' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100